Capricor Therapeutics (CAPR)
(Delayed Data from NSDQ)
$5.41 USD
+0.26 (5.05%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $5.41 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Capricor Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 39 | 41 | 35 | 33 | 10 |
Receivables | 10 | 1 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 1 | 1 | 1 |
Total Current Assets | 51 | 43 | 36 | 34 | 11 |
Net Property & Equipment | 6 | 5 | 2 | 1 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 59 | 50 | 41 | 35 | 11 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 5 | 4 | 3 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 24 | 18 | 0 | 0 | 0 |
Total Current Liabilities | 31 | 24 | 4 | 3 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 9 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 3 | 3 | 3 | 3 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 36 | 38 | 10 | 6 | 4 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 182 | 149 | 139 | 116 | 81 |
Retained Earnings | -159 | -137 | -108 | -88 | -74 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 23 | 12 | 31 | 28 | 7 |
Total Liabilities & Shareholder's Equity | 59 | 50 | 41 | 35 | 11 |
Total Common Equity | 23 | 12 | 31 | 28 | 7 |
Shares Outstanding | 30.70 | 25.20 | 24.10 | 20.40 | 5.20 |
Book Value Per Share | 0.74 | 0.47 | 1.30 | 1.38 | 1.32 |
Fiscal Year End for Capricor Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 39 | 29 | 38 | 45 |
Receivables | NA | 10 | 1 | 1 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 0 | 1 | 1 |
Total Current Assets | NA | 51 | 30 | 39 | 47 |
Net Property & Equipment | NA | 6 | 5 | 5 | 5 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 59 | 37 | 46 | 54 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 6 | 7 | 5 | 5 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 24 | 25 | 29 | 31 |
Total Current Liabilities | NA | 31 | 33 | 35 | 37 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 1 | 3 | 5 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 3 | 3 | 3 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 36 | 39 | 43 | 48 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 182 | 157 | 155 | 151 |
Retained Earnings | NA | -159 | -159 | -152 | -145 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 23 | -2 | 3 | 6 |
Total Liabilities & Shareholder's Equity | NA | 59 | 37 | 46 | 54 |
Total Common Equity | 0 | 23 | -2 | 3 | 6 |
Shares Outstanding | 31.50 | 30.70 | 25.70 | 25.20 | 25.20 |
Book Value Per Share | 0.00 | 0.74 | -0.07 | 0.11 | 0.25 |